← Eichor
Study identifier: NCT06519591 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Condition: Gastric Cancer Stage IV · Peritoneal Metastases  ·  Sponsor: Ruijin Hospital

PhasePhase 2
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.

This description comes directly from the study's public registry record.

Talk to the study team

Zhongyin Yang, PhD  ·  8621-64370045  ·  jeffreyyong@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin Hospital Shanghai Jiao Tong University School of MedicineShanghai, Huangpu District, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06519591